Limin Co., Ltd. announced that Inner Mongolia Xinweiyuan Biochemical Co., Ltd., a wholly-owned subsidiary of the company, obtained a filing notice for the synthetic biology R&D center and the intelligent manufacturing of synthetic biological products issued by the Inner Mongolia Dalat Development and Reform Commission. The project plans to invest 200 million yuan to mainly build a synthetic biology research and development center, an intelligent synthetic biological product manufacturing workshop and related auxiliary supporting facilities to produce ethyl polymycin and dinanping A biological products. After completion, it will produce 100 tons of ethyl polymycin biological products and 1 ton of dinanping A biological products per year after completion. The project still needs to complete administrative approvals such as EIA in the future.

Limin Co., Ltd. announced that Inner Mongolia Xinweiyuan Biochemical Co., Ltd., a wholly-owned subsidiary of the company, obtained a filing notice for the synthetic biology R&D center and the intelligent manufacturing of synthetic biological products issued by the Inner Mongolia Dalat Development and Reform Commission. The project plans to invest 200 million yuan to mainly build a synthetic biology research and development center, an intelligent synthetic biological product manufacturing workshop and related auxiliary supporting facilities to produce ethyl polymycin and dinanping A biological products. After completion, it will produce 100 tons of ethyl polymycin biological products and 1 ton of dinanping A biological products per year after completion. The project still needs to complete administrative approvals such as EIA in the future.